Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.
Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study[1].
[1]. van Andel L, et al. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 19;1040:14-21.
















